Step 1: Antiphospholipid antibody syndrome (APS) is diagnosed by combining a clinical criterion (vascular thrombosis or pregnancy morbidity) with a laboratory criterion (a persistently positive antiphospholipid antibody).
Step 2: The three accepted laboratory tests (Sapporo/Sydney criteria) are lupus anticoagulant, anticardiolipin antibody, and anti-beta 2 glycoprotein I antibody, each confirmed on two occasions at least 12 weeks apart.
Step 3: Among the options offered, anti-beta 2 glycoprotein I antibody is one of these defining laboratory criteria for APS.
Step 4: Beta 2 microglobulin (option A) is unrelated; it is a marker used in renal and myeloma assessment, not APS, and must not be confused with beta 2 glycoprotein I.
Step 5: Antinuclear antibody (option B) is a screening test for systemic lupus erythematosus and other connective tissue diseases, and anti-centromere antibody (option C) is associated with limited cutaneous systemic sclerosis (CREST); neither defines APS.
Conclusion: The correct answer is anti beta 2 glycoprotein I antibody.